The pharmaceutical industry has increasingly been adopting artificial intelligence – which has demonstrated the ability to predict instances of schizophrenia with 74% accuracy.
Researchers are using artificial intelligence to catalyze drug discovery and preclinical drug development - improving predictive models to guide efficient design and optimizing multi-drug regimens, as two recent examples.
Iqvia is expanding its alliance with Salesforce through which the companies will release SaaS and technology-enabled services to automate clinical trial processes and reduce patient burden.
Fusion Antibodies revenue grew 41% in FY2018, and while “pop up consultants” have created new competition, the CRO is differentiating itself by investing in its services and focusing on quality.
The multi-phase collaboration between WuXi AppTec Research Service Division and Cyclica looks to advance polypharmacology in drug discovery using AI-augmented technology.
The industry is increasingly engaging in collaborations to gain access to technology, such as AI, which is being touted as a potential solution to some of the most challenging aspects of running clinical trials.
QuintilesIMS has announced an alliance with Salesforce through which the companies aim to “equip and enable” customers to meet future healthcare challenges.
Adents and Microsoft have introduced a new platform that allows contract manufacturing organizations (CMOs) to leverage data generated during the serialization process.
